Low dose RLS103

DRUG2 trials

Sponsors

Receptor Life Sciences

Conditions

EpilepsySocial Anxiety Disorder

Phase 1

Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)

WithdrawnNCT05429788

Receptor Life SciencesSocial Anxiety Disorder

Start: 2022-05-18End: 2022-11-08Updated: 2024-04-02

Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy

TerminatedNCT05678881

Receptor Life SciencesEpilepsy

Start: 2022-04-25End: 2024-02-23Updated: 2024-05-02